Archive · 10 Nov 2025
MediTrust Health and Sino Biopharm Forge Strategic Alliance at CIIE 2025 for Drug-Insurance Integration
Imagine two big companies, Sino Biopharm (which makes medicines) and MediTrust Health (which works with insurance and helps people pay for healthcare).
They decided to work together at a big event called CIIE.
Their goal is to find new ways for insurance to help people pay for new and special medicines sooner.
This can make it easier for sick people to get the treatments they need without paying too much.
It also helps the medicine companies keep making new drugs.
They plan to use smart technology, like AI, to make this process smoother.
This partnership is also part of a larger plan for China to have better healthcare for everyone by the year 2030.
Sino Biopharm and MediTrust Health signed a strategic cooperation agreement at the 8th China International Import Expo (CIIE) in Shanghai.
The partnership aims to create a new model for integrating drug access with commercial health insurance.
This collaboration seeks to enable earlier patient access to high-quality, affordable innovative drugs.
Both companies will leverage AI and data collaboration to explore innovative payment solutions.
The initiative supports China's 'Healthy China 2030' strategy by enhancing drug accessibility and creating a mutually beneficial ecosystem.
- Who
- Sino Biopharmaceutical Limited (Sino Biopharm) and Shanghai MediTrust Health Technology Group Co., Ltd. (MediTrust Health)
- What
- Signed a strategic cooperation agreement to explore a new model of drug-insurance integration.
- When
- November 10, 2025
- Where
- Shanghai, during the 8th China International Import Expo (CIIE).
- Why
- To help more patients access high-quality, affordable medicines earlier, ease pressure on public medical insurance, and foster sustainable industry cycles.
- Event
- 8th China International Import Expo (CIIE) 2025
- Date
- November 10, 2025
- Location
- Shanghai
- Companies Involved
- Sino Biopharmaceutical Limited (Sino Biopharm) and Shanghai MediTrust Health Technology Group Co., Ltd. (MediTrust Health)
- Sino Biopharm Revenue
- Approximately RMB 30 billion annually
- Sino Biopharm Global Ranking
- 38th among Top 50 Global Pharmaceutical Companies
- MediTrust Health Policies Serviced (as of Dec 31, 2024)
- Approximately 393 million commercial health insurance policies
- MediTrust Health Cumulative Patient Savings
- RMB 6.7 billion